Literature DB >> 22520979

Targeting angiogenesis in gynecologic cancers.

Behrouz Zand1, Robert L Coleman, Anil K Sood.   

Abstract

Gynecologic malignancies carry an estimated incidence of 83,750 cases per year and estimated mortality rate of more than 27,000 women per year. New therapies and therapeutic approaches are needed to improve the outlook for women with gynecologic cancers. Recent insights at the molecular and cellular levels are paving the way for a more directed approach to target mechanisms driving tumorigenesis. This article reviews the roles of new and emerging antiangiogenesis drugs, summarizes the data obtained from clinical trials of antiangiogenic agents, and discusses trials under way to address the role of such strategies in gynecologic cancers.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22520979      PMCID： PMC3334841          DOI： 10.1016/j.hoc.2012.01.009

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  107 in total

1.  Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.

Authors:  Jason A Konner; Diana M Grabon; Scott R Gerst; Alexia Iasonos; Howard Thaler; Sandra D Pezzulli; Paul J Sabbatini; Katherine M Bell-McGuinn; William P Tew; Martee L Hensley; David R Spriggs; Carol A Aghajanian
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

2.  Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

Authors:  Jonathan A Ledermann; Allan Hackshaw; Stan Kaye; Gordon Jayson; Hani Gabra; Iain McNeish; Helena Earl; Tim Perren; Martin Gore; Mojca Persic; Malcolm Adams; Lindsay James; Graham Temple; Michael Merger; Gordon Rustin
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

Review 3.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Authors:  Xiaolei Zhu; Shenhong Wu; William L Dahut; Chirag R Parikh
Journal:  Am J Kidney Dis       Date:  2007-02       Impact factor: 8.860

4.  Sunitinib malate.

Authors:  Hassane Izzedine; Irina Buhaescu; Olivier Rixe; Gilbert Deray
Journal:  Cancer Chemother Pharmacol       Date:  2006-11-30       Impact factor: 3.333

5.  VEGF(165) mediates glomerular endothelial repair.

Authors:  T Ostendorf; U Kunter; F Eitner; A Loos; H Regele; D Kerjaschki; D D Henninger; N Janjic; J Floege
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

6.  Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial.

Authors:  J E Kurtz; A-C Hardy-Bessard; M Deslandres; S Lavau-Denes; R Largillier; C Roemer-Becuwe; B Weber; C Guillemet; D Paraiso; E Pujade-Lauraine
Journal:  Gynecol Oncol       Date:  2009-02-15       Impact factor: 5.482

7.  Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.

Authors:  Fiona Simpkins; Jerome L Belinson; Peter G Rose
Journal:  Gynecol Oncol       Date:  2007-07-23       Impact factor: 5.482

8.  Expression of epidermal growth factor receptor in carcinoma of the cervix.

Authors:  J W Kim; Y T Kim; D K Kim; C H Song; J W Lee
Journal:  Gynecol Oncol       Date:  1996-02       Impact factor: 5.482

9.  A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.

Authors:  Jason Konner; Russell J Schilder; Felicia A DeRosa; Scott R Gerst; William P Tew; Paul J Sabbatini; Martee L Hensley; David R Spriggs; Carol A Aghajanian
Journal:  Gynecol Oncol       Date:  2008-06-13       Impact factor: 5.482

10.  Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

Authors:  Doris R Siwak; Mark Carey; Bryan T Hennessy; Catherine T Nguyen; Mollianne J McGahren Murray; Laura Nolden; Gordon B Mills
Journal:  J Oncol       Date:  2009-11-19       Impact factor: 4.375
View more
  3 in total

1.  Binding of Intracellular Myeloperoxidase to αV/β1 Integrin Serves as a Mechanism of Survival in Epithelial Ovarian Cancer.

Authors:  Amy K Harper; Thea K Kirsch-Mangu; Hala Lutfi; Robert T Morris; Ghassan M Saed
Journal:  Reprod Sci       Date:  2022-07-07       Impact factor: 3.060

2.  A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

Authors:  Richard T Penson; Kathleen M Moore; Gini F Fleming; Patricia Braly; Veronica Schimp; Hoa Nguyen; Ursula A Matulonis; Susana Banerjee; Paul Haluska; Martin Gore; Diane C Bodurka; Rebecca R Hozak; Adarsh Joshi; Yihuan Xu; Jonathan D Schwartz; William P McGuire
Journal:  Gynecol Oncol       Date:  2014-07-10       Impact factor: 5.482

Review 3.  Angiogenesis in Gynecological Cancers: Role of Neurotrophins.

Authors:  Maritza P Garrido; Ignacio Torres; Margarita Vega; Carmen Romero
Journal:  Front Oncol       Date:  2019-09-19       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.